Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Conference, Trade Show

Compass Therapeutics to Present Preclinical Data on a Novel PD-1/PD-L1 Bispecific Antibody and from its Proprietary Innate Cell Engager Platform at the 2019 SITC Meeting


Compass Therapeutics, a clinical-stage biotechnology company focused on drugging the human immune synapse to treat human diseases, today announced two upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting, which is being held November 6-10 in National Harbor, MD.

The first poster will show recent data on CTX-8371, a novel bispecific antibody targeting the inhibitory receptor PD-1 and its ligand, PD-L1. CTX-8371 was discovered in an unbiased screen of checkpoint bispecifics using Compass's proprietary StitchMabsTM technology. CTX- 8371 demonstrates significantly increased potency in vitro and in vivo compared to combinations of monoclonals blocking PD-1 and PD-L1. Mechanistic studies of CTX-8371 suggest that the enhanced potency is associated with its unique ability to drive PD-1 downregulation from the surface of effector T cells.

The second poster presentation describes Compass's innate-cell engager platform. Leveraging its common light-chain technology, Compass has developed a series of bispecific antibodies that simultaneously engage tumor associated antigens and the activating receptor NKp30 expressed on NK cells and other innate effector cells to promote potent and highly selective tumor cell killing.

Full details of the presentations are as follows:

Poster title: CTX-8371, a novel bispecific targeting both PD-1 and PD-L1, is more potent than combination anti-PD-1 and PD-L1 therapy and provides enhanced protection from tumors in vivo
Abstract ID: P251
Date & time: Friday, Nov. 8, 7:00 am - 8:00 pm ET
Location: Poster Hall (Prince George AB), Gaylord National Hotel & Convention Center, National Harbor, Md.

Poster title: A novel class of multi-specific antibodies targeting NKp30 on innate immune cells
Abstract ID: P7770
Date & time: Saturday, Nov. 9, 7:00 am - 8:00 pm ET
Location: Poster Hall (Prince George AB), Gaylord National Hotel & Convention Center, National Harbor, Md.

About Compass Therapeutics

Compass Therapeutics is a clinical-stage biotechnology company targeting the human immune synapse with a new generation of monoclonal and multispecific antibody therapeutics. Compass has broadly drugged the immune system by generating epitopically diverse antibody panels to more than 40 targets across all immune cell types and is leveraging its proprietary StitchMabsTM and common light-chain based multispecific platforms to empirically identify combinations and multispecifics with optimized activity. The company's lead product candidate, CTX-471, is a fully human agonistic antibody of CD137, which is in a Phase 1 study in patients with inadequate responses to PD-1/PD-L1 checkpoint inhibitors. Compass is also progressing several preclinical assets including a novel class of innate-cell engaging bispecifics targeting NKp30 and multiple bispecific checkpoint programs. The company's offices and labs are based in Kendall Square in Cambridge, Mass.


These press releases may also interest you

at 16:05
Leading mobile payments company WorldRemit has appointed seasoned digital executive Scott Eddington to lead the Asia Pacific business as it positions itself to help even more customers make secure, quick and affordable cross border payments. Scott...

at 14:00
Mag Max 3A is a 3 amp battery adapter that powers DSLRs, mirrorless cameras, audio recorders, LED lights, monitors and other accessories (including your cellphone and other USB-powered devices) via one of the most common batteries on the market? the...

at 13:24
NASA and SpaceX completed a launch escape demonstration of the company's Crew Dragon spacecraft and Falcon 9 rocket Sunday. This was the final major flight test of the spacecraft before it begins carrying astronauts to the International Space Station...

at 11:00
Choosing the best drone on the market is not easy, as the offering is so wide and varied. DJI offers a solution for every need: from the extra-lightweight Mavic Mini, which films incredibly smooth videos, to more professional drones like the Mavic 2...

at 08:05
Imaging USA ? Booth #375 ? Ontrack, LLC, the world's leading data recovery service provider, today announced Gold Corporate Member status with Professional Photographers of America, (PPA). PPA members can now receive exceptional member discounts and...

at 02:33
Cellcom Israel Ltd. (the "Company") announced today that Mr. Ron Shvili, the Company's CTO, informed the Company of his intention to resign as CTO in the near term at a date yet to be determined. Mr. Nir Sztern, the Company's departing CEO said:...



News published on 24 october 2019 at 08:05 and distributed by: